New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease

Research output: Contribution to journalArticle

Abstract

Antitumor necrosis factor α agents have dramatically changed the management of inflammatory bowel disease (IBD). However, a significant proportion of patients does not respond or lose response over time. Hence, there is an urgent need for new molecules, with different mechanisms of action, and with a targeted and more effective approach. These new drugs include either small molecules or biological agents. We describe the three most promising classes of molecules in the field of IBD: anti-adhesion, anti-interleukin 12/23 and anti-Janus Kinases therapies.

Original languageEnglish
Pages (from-to)113-120
Number of pages8
JournalScandinavian Journal of Gastroenterology
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Keywords

  • Adhesion molecules
  • Anti-integrins
  • Anti-interleukin 12/23
  • Anti-Janus kinases
  • Crohn's disease
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Fingerprint Dive into the research topics of 'New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease'. Together they form a unique fingerprint.

  • Cite this